Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHI SQUARE: CER-001 in Acute Coronary Syndrome
NCT01201837Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- Mar 2011
- Primary completion
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 4
01
Overview
A Phase 2 trial of CER-001 in acute coronary syndrome (ACS), sponsored by ABIONYX Pharma. Started Mar 2011; status: completed.
02
Drugs
CER-001
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01201837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01201837.